Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783705 · ClinicalTrials.gov registry record · Phase 2
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
A Phase 2 study of Non-Small Cell Lung Cancer and Squamous Lung Dysplasia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 4
- Study locations
NCT00783705: Completed Phase 2 study of Non-Small Cell Lung Cancer and Squamous Lung Dysplasia, sponsored by National Cancer Institute (NCI).
NCT00783705 is a Phase 2 study of Non-Small Cell Lung Cancer and Squamous Lung Dysplasia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 85 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00783705, a Phase 2 study of Non-Small Cell Lung Cancer and Squamous Lung Dysplasia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 4
- Study locations
Study Summary
This randomized phase II trial is studying inositol to see how well it works compared with a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of inositol may prevent lung cancer. It is not yet known whether inositol is more effective than a placebo in preventing lung cancer in smokers with bronchial dysplasia.
Primary Outcome
The definitions of responses are: Complete response: regression of all dysplastic lesion (DL) found at baseline to lesions that were no worse than hyperplasia and no new DL that were mild dysplasia or worse; Partial response: regression of some but not all of the DL with no new lesions that are mild dysplasia or worse; Progressive disease: progression of one or more sites by two or more grades or new DL that were mild dysplasia or worse; Stable disease: no complete response, partial response or
Conditions Studied
Interventions
- OTHER placebo
- DRUG inositol
Study Locations (4)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
New Mexico
- Albuquerque Veterans Administration Medical Center - Albuquerque
British Columbia
- BCCA-Vancouver Cancer Centre - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2008-11 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
What the finished NCT00783705 record still lists
NCT00783705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00783705 reports a single indexed study location in Arizona, Minnesota, New Mexico.
Frequently Asked Questions
What is clinical trial NCT00783705 about?
NCT00783705 is a clinical study titled "Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia". This randomized phase II trial is studying inositol to see how well it works compared with a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of inositol may prevent lung cancer. ...
What is the current status of trial NCT00783705?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2008-11. Estimated completion is 2014-05.
What conditions does trial NCT00783705 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Squamous Lung Dysplasia.
What interventions are being tested in trial NCT00783705?
The interventions under investigation include: placebo (OTHER), inositol (DRUG).
Who is sponsoring clinical trial NCT00783705?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00783705 being conducted?
This trial has 4 study locations across Arizona, Minnesota, New Mexico, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00783705's enrollment target sits among peer trials
85 259th of 454 higher than 192 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia